<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349762</url>
  </required_header>
  <id_info>
    <org_study_id>HE-201709</org_study_id>
    <nct_id>NCT03349762</nct_id>
  </id_info>
  <brief_title>Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery</brief_title>
  <official_title>A Real-World Study Investigating Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xi Shan Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Huaier granules for Prevention of Recurrence and
      Metastasis of colorectal cancer patients following radical surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multisite, open-label, prospective study investigating Huaier Granule for
      Prevention of Recurrence and Metastasis of colorectal cancer patients following radical
      surgery，to evaluate the efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival(DFS)</measure>
    <time_frame>36 months</time_frame>
    <description>Disease free survival (DFS) was defined as the time from participation to the time of tumor recurrence or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>36 months</time_frame>
    <description>OS was defined as the time from participation to death from any cause or last patient last visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local recurrence-Free Survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>The proportion of Local recurrence-Free Survival subjects to the total number of subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distant Metastasis-Free Survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>The proportion of Distant Metastasis-Free Surviva subjects to the total number of subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QOL)</measure>
    <time_frame>36 months</time_frame>
    <description>Quality of Life (QOL) were measured using supplemental quality of life questions. Item score range（12 items）: 1 (worst symptom) to 5 (no symptom). Change: score at 36 months minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of Adverse events (AE)</measure>
    <time_frame>36 months</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Adverse events</measure>
    <time_frame>36 months</time_frame>
    <description>An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunity function</measure>
    <time_frame>36 months</time_frame>
    <description>Immunity function was measured with Immune cells counts and positive rate.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3060</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Observational 1</arm_group_label>
    <description>Radiotherapy or Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational 2</arm_group_label>
    <description>Huaier Granule &amp; Radiotherapy or chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational 3</arm_group_label>
    <description>Huaier Granules</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Colorectal cancer patients after radical surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females ages 18-75 years;

          2. The first time to the therapy of patients who received the radical surgery within two
             months, Postoperative histopathology confirms the diagnosis of colorectal cancer with
             stage IIB, IIC and III ( TNM classification)

          3. ECOG score of 0-2;

          4. No history of malignant tumors;

          5. The patients are volunteered for the study, sign informed consent form and cooperate
             with Investigator to collect data.

        Exclusion Criteria:

          1. Patients have basic diseases including heart diseases, cerebrovascular disease, lung
             disease, severe hypertension or diabetes with poor glycemic control;

          2. confirmed infections after surgery ;

          3. Patients who have post-surgery complications or who are currently under the influence
             of the radical surgery for colorectal cancer;

          4. Being infected with syphilis or with other blood-borne infectious diseases;

          5. Pregnancy or lactation; or women of childbearing potential not using contraception;

          6. Patients who have taken Traditional Chinese Medicines with efficacy and indications
             similar to that of Huaier granule - including, but not limited to, compound Banmao
             capsule., Huachansu capsule, Kangai Injection and Pingxiao tablets;

          7. Patients who are suffering from mental illness or Conditions that are considered not
             suitable for this study investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xishan Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xishan Wang, Professor</last_name>
    <phone>+0086-13552367779</phone>
    <email>wangxishanzy@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dalu kong, professor</last_name>
      <phone>1862221078</phone>
      <email>kongdl@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Xi Shan Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Huaier Granule</keyword>
  <keyword>multisite</keyword>
  <keyword>open-label</keyword>
  <keyword>prospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

